In a phase 2 clinical trial, PFS of 5.9 months was achieved with the HDAC inhibitor, vorinostat for relapse/refractory MCL (n = 9) however, vorinostat alone was not considered a promising agent [196]. The gene discussed is HDAC9; the disease is mantle cell lymphoma.